SEC Filing · 4
ArriVent BioPharma, Inc.
AVBPNASDAQEQUITYCurrent
SEC Filing
Company context
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗